Third harmonic bio inc THRD.US 總覽分析
THRD 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
THRD 近期報酬表現
-0.19%
Third harmonic bio inc
1.99%
同產業平均
-0.64%
S&P500
與 THRD 同產業的標的表現
- VNDA Vanda pharmaceuticals inc.價值 4 分趨勢 3 分波段 4 分籌碼 1 分股利 1 分查看更多
THRD 公司資訊
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.